Thailanstatin A is an ultra-potent spliceosome inhibitor targeting SF3b with sub-nM activity against cancer cells. As a proven ADC payload, it conjugates directly to lysines on antibodies, enabling “linker-less” ADC design for next-generation oncology therapeutics.
Usually ships within 24 hours.